JP2013534227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534227A5
JP2013534227A5 JP2013524362A JP2013524362A JP2013534227A5 JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5 JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5
Authority
JP
Japan
Prior art keywords
nasal
nose
powder
ingested
sucking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534227A (ja
JP6049617B2 (ja
Filing date
Publication date
Priority claimed from DE102010034699A external-priority patent/DE102010034699A1/de
Application filed filed Critical
Publication of JP2013534227A publication Critical patent/JP2013534227A/ja
Publication of JP2013534227A5 publication Critical patent/JP2013534227A5/ja
Application granted granted Critical
Publication of JP6049617B2 publication Critical patent/JP6049617B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524362A 2010-08-18 2011-07-19 Fak阻害剤としてのピリミジン誘導体 Expired - Fee Related JP6049617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010034699A DE102010034699A1 (de) 2010-08-18 2010-08-18 Pyrimidinderivate
DE102010034699.3 2010-08-18
PCT/EP2011/003597 WO2012022408A1 (de) 2010-08-18 2011-07-19 Pyrimidinderivate als fak inhibitoren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016153334A Division JP6441861B2 (ja) 2010-08-18 2016-08-04 Fak阻害剤としてのピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2013534227A JP2013534227A (ja) 2013-09-02
JP2013534227A5 true JP2013534227A5 (cg-RX-API-DMAC7.html) 2016-01-07
JP6049617B2 JP6049617B2 (ja) 2016-12-21

Family

ID=44504442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524362A Expired - Fee Related JP6049617B2 (ja) 2010-08-18 2011-07-19 Fak阻害剤としてのピリミジン誘導体
JP2016153334A Expired - Fee Related JP6441861B2 (ja) 2010-08-18 2016-08-04 Fak阻害剤としてのピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016153334A Expired - Fee Related JP6441861B2 (ja) 2010-08-18 2016-08-04 Fak阻害剤としてのピリミジン誘導体

Country Status (17)

Country Link
US (1) US8906916B2 (cg-RX-API-DMAC7.html)
EP (1) EP2606034B1 (cg-RX-API-DMAC7.html)
JP (2) JP6049617B2 (cg-RX-API-DMAC7.html)
CN (1) CN103052627B (cg-RX-API-DMAC7.html)
AR (1) AR082722A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011291110B2 (cg-RX-API-DMAC7.html)
CA (1) CA2808540C (cg-RX-API-DMAC7.html)
DE (1) DE102010034699A1 (cg-RX-API-DMAC7.html)
DK (1) DK2606034T3 (cg-RX-API-DMAC7.html)
ES (1) ES2572740T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160562T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027846T2 (cg-RX-API-DMAC7.html)
IL (1) IL224751A (cg-RX-API-DMAC7.html)
PL (1) PL2606034T3 (cg-RX-API-DMAC7.html)
RS (1) RS54882B1 (cg-RX-API-DMAC7.html)
SI (1) SI2606034T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012022408A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
WO2012110773A1 (en) * 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5937112B2 (ja) * 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited 選択的fak阻害剤
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
US9238644B2 (en) 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
EP2885292A4 (en) * 2012-08-17 2015-07-01 Cancer Therapeutics Crc Pty Ltd VEGFR3 INHIBITORS
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5阻害剤
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
WO2015123722A1 (en) * 2014-02-19 2015-08-27 Bionomics Limited Inhibitors
WO2016033100A1 (en) * 2014-08-25 2016-03-03 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
CA2463989C (en) * 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
KR20080004585A (ko) * 2005-04-08 2008-01-09 바이엘 파마슈티칼스 코포레이션 피리미딘 유도체 및 암의 치료에서의 이의 용도
CN103588704B (zh) 2007-03-16 2016-09-14 斯克里普斯研究学院 粘着斑激酶抑制剂
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CA2986640C (en) * 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
AR074209A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
JP5937112B2 (ja) * 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited 選択的fak阻害剤
WO2012110773A1 (en) * 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors

Similar Documents

Publication Publication Date Title
JP2014509313A5 (cg-RX-API-DMAC7.html)
JP2013534227A5 (cg-RX-API-DMAC7.html)
JP2014526447A5 (cg-RX-API-DMAC7.html)
JP2013544781A5 (cg-RX-API-DMAC7.html)
JP2013541565A5 (cg-RX-API-DMAC7.html)
JP2015505541A5 (cg-RX-API-DMAC7.html)
Doktorovova et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
JP2013538214A5 (cg-RX-API-DMAC7.html)
RU2015121091A (ru) Порошки для ингаляции с ультранизкой плотностью
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
MX371521B (es) Sistema de inhalacion de polvo seco.
BR112013022249B8 (pt) Dispositivo de distribuição de droga nasal
WO2014012069A3 (en) Dry powder drug delivery systems and methods
JP2017502064A5 (cg-RX-API-DMAC7.html)
ATE527976T1 (de) Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
WO2010029441A3 (en) Nasal delivery
WO2013090841A3 (en) Aerosolization apparatus for inhalation profile-independent drug delivery
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
WO2013038268A8 (en) Tamper resistant immediate release formulations
JP2014530231A5 (cg-RX-API-DMAC7.html)
MY160652A (en) Pharmaceutical composition for oral administration
WO2011008662A9 (en) Powder delivery devices and methods of using the same